EUVIMEDEUVIMED entdecken
Crossref

Fluorofenidone mitigates liver fibrosis through GSK-3β modulation and hepatocyte protection in a 3D tissue-engineered model

Long Huang, Yu Chen, Xu Fan, Xiaohui Zhang, Xue Wang, Lin Liu, Tianhui Liu, Ping Wang, Anjian Xu, Xinyan Zhao, Min Cong

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.114209 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Long Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Liver Research Center, Beijing Friendship Hospital, Capital Medical University,Beijing, China; State Key Laboratory of Digestive Health and National …. Hauptthemen laut MEDLINE: Glycogen Synthase Kinase 3 beta, Pyridones, Hepatocytes, Liver Cirrhosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver fibrosis, a critical stage in chronic liver disease progression, presents a significant global health challenge. This study investigates the antifibrotic and hepatoprotective properties of fluorofenidone (AKF-PD) using a 3D tissue-engineered model. A 3D in vitro liver fibrosis model was developed using decellularized rat liver scaffolds seeded with hepatocytes, hepatic stellate cells (HSCs), and sinusoidal endothelial cells to replicate the multicellular liver microenvironment. The model was stimulated with carbon tetrachloride (CCl4) to induce fibrotic conditions, resulting in collagen deposition, HSC activation, and elevated fibrosis markers. Parallel in vivo studies employed C57BL/6J mice with CCl4-induced liver fibrosis. The antifibrotic and hepatoprotective effects of AKF-PD were evaluated by assessing collagen deposition, fibrosis markers, and hepatocyte apoptosis. Oxidative stress markers and inflammation-related proteins were also measured. Molecular docking identified GSK-3β as a target protein of AKF-PD, and subsequent analyses explored the GSK-3β/β-catenin and Nrf2/HO-1 signaling pathways. AKF-PD demonstrated significant efficacy in reducing fibrosis markers and protecting hepatocytes by inhibiting apoptosis and oxidative stress. Mechanistically, AKF-PD targets the GSK-3β/β-catenin pathway, suppressing β-catenin-mediated pro-fibrotic gene expression, while activating the Nrf2/HO-1 pathway to mitigate oxidative stress, thereby reducing hepatocyte apoptosis. These findings are consistent with results from CCl4-induced mouse fibrosis models, validating the 3D model's applicability for preclinical drug evaluation. This 3D liver fibrosis model provides a physiologically relevant platform for studying fibrosis and anti-fibrotic mechanisms, highlighting AKF-PD's promise as a therapeutic agent and advancing liver fibrosis research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycogen Synthase Kinase 3 betaPyridonesHepatocytesLiver CirrhosisAnimalsMice, Inbred C57BLMaleCarbon TetrachlorideMiceRatsTissue EngineeringHepatic Stellate CellsApoptosisLiverSignal TransductionHumansOxidative Stress

Stichwörter der Autor:innen

3D tissue-engineeredAKF-PDGSK-3β/β-cateninNrf2/HO-1

Substanzen

Glycogen Synthase Kinase 3 betaPyridonesCarbon Tetrachloride5-methyl-1-(3-fluorophenyl)-2-(1H)-pyridone

Autor:innen und Institutionen

  • Liver Research Center, Beijing Friendship Hospital, Capital Medical University,Beijing, China; State Key Laboratory of Digestive Health and National Clinical Research Center of Digestive Disease, Beijing, China.
  • Fourth Department of Liver Disease, Beijing Youan Hospital, Capital Medical University; Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing, China.
  • Experimental and Translational Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • Liver Research Center, Beijing Friendship Hospital, Capital Medical University,Beijing, China; State Key Laboratory of Digestive Health and National Clinical Research Center of Digestive Disease, Beijing, China. Electro…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Huang, L., Chen, Y., Fan, X., Zhang, X., Wang, X., Liu, L., Liu, T., Wang, P., Xu, A., Zhao, X., & Cong, M. (2025). Fluorofenidone mitigates liver fibrosis through GSK-3β modulation and hepatocyte protection in a 3D tissue-engineered model. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.114209

Vancouver

Huang L, Chen Y, Fan X, Zhang X, Wang X, Liu L, et al. Fluorofenidone mitigates liver fibrosis through GSK-3β modulation and hepatocyte protection in a 3D tissue-engineered model. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.114209

BibTeX
@article{Huang2025,
  author = {Huang, Long and Chen, Yu and Fan, Xu and Zhang, Xiaohui and Wang, Xue and Liu, Lin and Liu, Tianhui and Wang, Ping and Xu, Anjian and Zhao, Xinyan and Cong, Min},
  title = {Fluorofenidone mitigates liver fibrosis through GSK-3β modulation and hepatocyte protection in a 3D tissue-engineered model},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.114209}
}
Kostenlos starten →